TED on MSNOpinion
A vaccine scientist went on a first date - then he said the words she was trained to fight
A vaccine scientist tells the story of a first date that turned into a lesson about vaccine doubt, long before the COVID ...
Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...
In addition to long-standing engineering partnerships with Columbia University and Dartmouth College, Hobart and William ...
The flu might be a relatively common illness, but it’s nothing to mess around with. The Centers for Disease Control and Prevention (CDC) estimates that in a typical year, the flu kills tens of ...
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was ...
Building on recent successes, scientists are focused on a promising new frontier: sending tiny particles into the body to ...
The tables have turned for the U.S. biosimilars market. With more than a decade since the first FDA biosim approval, strong launches to biologic copies to AbbVie’s Humira, J&J’s Stelara and ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value.
Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts ...
Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results